GH Research PLC operates at the forefront of psychedelic-inspired medicines targeting treatment-resistant depression, progressing its lead candidates GH001 and GH002 through IND status and Phase 3 preparation, supported by proprietary delivery technology. Financially, the company has ramped up R&D spending which has driven a year-over-year decline in net income by approximately 24%, yet maintained strong liquidity with cash and equivalents growing from $183 million to nearly $281 million over 2024–2025. The firm’s capital allocation focuses on drug development, IP protection, and preparing for potential commercialization with no dividend or buyback activity, reflecting its clinical-stage biotech status. Key risks include clinical trial outcomes, regulatory hurdles, foreign exchange volatility, and cybersecurity threats—all managed within an evolving corporate governance framework under Irish law.